Cyclerion Therapeutics Valuation
| CYCN Stock | USD 2.82 0.07 2.55% |
Based on Macroaxis valuation methodology, the firm appears to be fairly valued. Cyclerion Therapeutics shows a prevailing Real Value of $2.8 per share. The current price of the firm is $2.82. Our model approximates the value of Cyclerion Therapeutics from analyzing the firm fundamentals such as return on equity of -0.3, and Profit Margin of (1.53) % as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Cyclerion Therapeutics' valuation include:
Price Book 0.8112 | Enterprise Value | Enterprise Value Ebitda 0.563 | Price Sales 3.5897 | Enterprise Value Revenue 1.9738 |
Fairly Valued
Today
Please note that Cyclerion Therapeutics' price fluctuation is dangerous at this time. Calculation of the real value of Cyclerion Therapeutics is based on 3 months time horizon. Increasing Cyclerion Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Cyclerion Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Cyclerion Stock. However, Cyclerion Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 2.82 | Real 2.8 | Target 4.0 | Hype 2.82 |
The intrinsic value of Cyclerion Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Cyclerion Therapeutics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Cyclerion Therapeutics helps investors to forecast how Cyclerion stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Cyclerion Therapeutics more accurately as focusing exclusively on Cyclerion Therapeutics' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Cyclerion Therapeutics' intrinsic value based on its ongoing forecasts of Cyclerion Therapeutics' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Cyclerion Therapeutics' closest peers.
Cyclerion Therapeutics Cash |
|
Cyclerion Valuation Trend
Knowing Cyclerion Therapeutics' actual value is paramount for traders when making sound investment determinations. Using both Cyclerion Therapeutics' enterprise value as well as its market capitalization is the best way to estimate the value of the company and is usually enough for investors to make market timing decisions.
Cyclerion Therapeutics Total Value Analysis
Cyclerion Therapeutics is currently forecasted to have valuation of 3.95 M with market capitalization of 7.18 M, debt of 725 K, and cash on hands of 30.32 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Cyclerion Therapeutics fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
3.95 M | 7.18 M | 725 K | 30.32 M |
Cyclerion Therapeutics Investor Information
About 27.0% of the company shares are held by company insiders. The company has price-to-book (P/B) ratio of 0.81. Some equities with similar Price to Book (P/B) outperform the market in the long run. Cyclerion Therapeutics recorded a loss per share of 1.21. The entity had not issued any dividends in recent years. The firm had 1:20 split on the 16th of May 2023. Based on the key indicators related to Cyclerion Therapeutics' liquidity, profitability, solvency, and operating efficiency, Cyclerion Therapeutics may be sliding down financialy. It has an above-average odds of going through some form of financial crisis next quarter.Cyclerion Therapeutics Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Cyclerion Therapeutics has an asset utilization ratio of 20.89 percent. This suggests that the Company is making $0.21 for each dollar of assets. An increasing asset utilization means that Cyclerion Therapeutics is more efficient with each dollar of assets it utilizes for everyday operations.Cyclerion Therapeutics Ownership Allocation
Cyclerion Therapeutics retains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares.Cyclerion Therapeutics Profitability Analysis
The company reported the previous year's revenue of 2 M. Net Loss for the year was (3.06 M) with profit before overhead, payroll, taxes, and interest of 2 M.About Cyclerion Therapeutics Valuation
We use absolute and relative valuation methodologies to arrive at the intrinsic value of Cyclerion Therapeutics. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Cyclerion Therapeutics based exclusively on its fundamental and basic technical indicators. By analyzing Cyclerion Therapeutics's financials, quarterly and monthly indicators, and their related drivers, we attempt to find the most accurate representation of Cyclerion Therapeutics's intrinsic value. As compared to an absolute model, our relative valuation model uses a comparative analysis of Cyclerion Therapeutics. We calculate exposure to Cyclerion Therapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Cyclerion Therapeutics's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 2.3 M | 1.6 M | |
| Pretax Profit Margin | (1.76) | (1.85) | |
| Operating Profit Margin | (2.09) | (2.19) | |
| Net Loss | (1.76) | (1.85) | |
| Gross Profit Margin | 0.78 | 0.90 |
Cyclerion Therapeutics Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 2.5 M |
Cyclerion Therapeutics Current Valuation Indicators
Cyclerion Therapeutics' valuation analysis is a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final Cyclerion Therapeutics' valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Cyclerion Therapeutics, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Cyclerion Therapeutics' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Cyclerion Therapeutics' worth.When determining whether Cyclerion Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Cyclerion Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Cyclerion Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Cyclerion Therapeutics Stock: Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cyclerion Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. To learn how to invest in Cyclerion Stock, please use our How to Invest in Cyclerion Therapeutics guide.You can also try the Portfolio Anywhere module to track or share privately all of your investments from the convenience of any device.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cyclerion Therapeutics. If investors know Cyclerion will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cyclerion Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.21) | Revenue Per Share | Quarterly Revenue Growth 0.141 | Return On Assets | Return On Equity |
The market value of Cyclerion Therapeutics is measured differently than its book value, which is the value of Cyclerion that is recorded on the company's balance sheet. Investors also form their own opinion of Cyclerion Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Cyclerion Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cyclerion Therapeutics' market value can be influenced by many factors that don't directly affect Cyclerion Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cyclerion Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Cyclerion Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cyclerion Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.